Pigmentation Disorders

Explore some of the key insights from EADV 2023: Prof. Thierry Passeron illuminates pigmentary disorders breakthroughs, Dr Raj Chovatiya unveils atopic dermatitis innovations, Prof. Leonardo Marini sheds light on aesthetic medicine developments, and Prof. Dedee Murrell reveals treatment progress exciting clinical trials and key discoveries in blistering and autoimmune diseases. Filmed in coverage of the EADV Annual Meeting. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress. 

Touch Medical Media coverage of data presented at EADV 2023: The phase 2b study evaluating upadacitinib (RINVOQ®) in adults with non-segmental vitiligo achieved the primary endpoint of percent change from baseline in Facial Vitiligo Area Scoring Index, with no new safety signals identified. touchDERMATOLOGY caught up with Prof. Thierry Passeron (University Hospital of Nice, Nice, […]

TRuE-V1 (NCT04052425) and TRuE-V2 (NCT04057573) were randomized, double-blind, vehicle-controlled phase 3 studies investigating ruxolitinib cream in adults and adolescents with vitiligo. touchIMMUNOLOGY were delighted to speak with Prof. Thierry Passeron (University Hospital of Nice, Nice, France) to discuss the rationale and findings from his pooled analysis looking at the effect of ruxolitinib cream on achievement of VASI50 by body region. The abstract 'Effect of Ruxolitinib Cream on Achievement of VASI50 by Body Region: Week 52 Pooled Analysis of the TRuE-V Phase 3 Studies.' (Abstract number: 3640) was presented at EADV 2022, 7-10 September, 2022. Questions Could you give us a brief overview of the clinical development of ruxolitinib cream which has led to its approval for the treatment of vitiligo? (0:11) What have been the efficacy and safety findings of the TRuE-V studies, and how clinically meaningful are these findings? (0:52) What was the rationale for the pooled analysis you are presenting? (1:45) What were the findings of this analysis and what are the implications of these findings? (2:38) What has been the clinical impact of ruxolitinib cream in this indication since its approval? (3:27) Disclosures: Thierry Passeron discloses consulting for Almirall, Abbvie, Amgen, Astellas, BMS, Celgene, Galderma, GSK, Incyte, Isocell, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Sanofi-Genzyme, SUN pharma, and UCB pharma; receiving grant/ research support from Abbvie, Almirall, BMS, Celgene, Incyte, Isocell, LEO Pharma, and Lilly; and receiving honoraria from Almirall, Abbvie, Amgen, Astellas, BMS, Celgene, Galderma, GSK, Incyte, Isocell, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Sanofi-Genzyme, SUN pharma, and UCB pharma. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress. 

TRuE-V1 (NCT04052425) and TRuE-V2 (NCT04057573) were randomized, double-blind, vehicle-controlled phase 3 studies that investigated ruxolinitib cream for the treatment of vitiligo over 52 weeks. We were delighted to speak to Dr. Amit G. Pandya (Palo Alto Foundation Medical Group, Sunnyvale, CA, USA) around the efficacy and safety findings from the TRuE-V phase 3 studies and […]

Vitiligo, a chronic autoimmune disorder characterized by skin depigmentation, has long posed challenges for effective treatment. Recent progress, however, has been made in the form of a cream containing ruxolitinib, a Janus kinase (JAK) 1/JAK2 inhibitor. This formulation has shown promising safety and efficacy results over the course of a 52-week period, offering hope to […]